An update on the management and prevention of cytomegalovirus infection following allogeneic hematopoietic stem cell transplantation

Future Virology

Volumn 10, Issue 2, 2015, Pages 113-134

  Romero, Pilar Pérez ^a   Blanco, Pilar ^a   Giménez, Estela ^b   Solano, Carlos ^b   Navarro, David ^b,c  

^a UNIVERSITY OF SEVILLE   (Spain)

^b HOSPITAL CLÍNICO UNIVERSITARIO   (Spain)

^c UNIVERSITY OF VALENCIA   (Spain)

Author keywords

allogeneic stem cell transplantation; CMV therapy; CMV vaccines; cytomegalovirus (CMV); immunological monitoring; real time PCR

Indexed keywords

ANTIVIRUS AGENT; ARTESUNATE; BENZIMIDAVIR; BRINCIDOFOVIR; CYCLOPROPAVIR; CYTOMEGALOVIRUS VACCINE; GANCICLOVIR; LEFLUNOMIDE; LETERMOVIR; NUCLEIC ACID; UNCLASSIFIED DRUG; VALGANCICLOVIR; VIRUS DNA;

ALLOGENEIC HEMATOPOIETIC STEM CELL TRANSPLANTATION; ANTIVIRAL THERAPY; COMPARATIVE STUDY; CYTOMEGALOVIRUS; CYTOMEGALOVIRUS INFECTION; EX VIVO STUDY; GENETIC RISK; HUMAN; IMMUNE RESPONSE; KINETICS; MORTALITY; PHASE 1 CLINICAL TRIAL (TOPIC); PHASE 2 CLINICAL TRIAL (TOPIC); PHASE 3 CLINICAL TRIAL (TOPIC); PRIORITY JOURNAL; REVIEW; T LYMPHOCYTE;

CYTOMEGALOVIRUS;

EID: 84923277628     PISSN: 17460794     EISSN: 17460808     Source Type: Journal    
DOI: 10.2217/fvl.14.102     Document Type: Review

References (212)

1. Boeckh M, Nichols WG, Papanicolaou G, Rubin R, Wingard JR, Zaia J. Cytomegalovirus in hematopoietic stem cell transplant recipients: current status, known challenges, and future strategies. Biol. Blood Marrow Transplant. 9(9), 543-558 (2003)
2. Ljungman P. CMV infections after hematopoietic stem cell transplantation. Bone Marrow Transplant. 42(Suppl. 1), S70-S72 (2008).
3. Ozdemir E, Saliba RM, Champlin RE et al. Risk factors associated with late cytomegalovirus reactivation after allogeneic stem cell transplantation for hematological malignancies. Bone Marrow Transplant. 40(2), 125-136 (2007).
4. Boeckh M, Leisenring W, Riddell SR et al. Late cytomegalovirus disease and mortality in recipients of allogeneic hematopoietic stem cell transplants: importance of viral load and T-cell immunity. Blood 101(2), 407-414 (2003).
5. Nichols WG, Corey L, Gooley T, Davis C, Boeckh M. High risk of death due to bacterial and fungal infection among cytomegalovirus (CMV)-seronegative recipients of stem cell transplants from seropositive donors: evidence for indirect effects of primary CMV infection. J. Infect. Dis. 185(3), 273-282 (2002).
6. Marr KA, Carter RA, Boeckh M, Martin P, Corey L. Invasive aspergillosis in allogeneic stem cell transplant recipients: changes in epidemiology and risk factors. Blood 100(13), 4358-4366 (2002).
7. Wang LR, Dong LJ, Zhang MJ, Lu DP. Correlations of human herpesvirus 6B and CMV infection with acute GVHD in recipients of allogeneic haematopoietic stem cell transplantation. Bone Marrow Transplant. 42(10), 673-677 (2008).
8. Garcia-Vidal C, Upton A, Kirby KA, Marr KA. Epidemiology of invasive mold infections in allogeneic stem cell transplant recipients: biological risk factors for infection according to time after transplantation. Clin. Infect. Dis. 47(8), 1041-1050 (2008).
9. Cantoni N, Hirsch HH, Khanna N et al. Evidence for a bidirectional relationship between cytomegalovirus replication and acute graft-versus-host disease. Biol. Blood Marrow Transplant. 16(9), 1309-1314 (2010).
10. Freeman RB. The 'indirect' effects of cytomegalovirus infection. Am. J. Transplant. 9(11), 2453-2458 (2009).
11. Gimenez E, Solano C, Nieto J et al. An investigation on the relationship between the occurrence of CMV DNAemia and the development of invasive aspergillosis in the allogeneic stem cell transplantation setting. J. Med. Virol. 86(4), 568-575 (2014).
12. Solano C, Munoz-Cobo B, Gimenez E et al. Pre-emptive antiviral therapy for active CMV infection in adult allo-SCT patients guided by plasma CMV DNAemia quantitation using a real-time PCR assay: clinical experience at a single center. Bone Marrow Transplant. 48(7), 1010-1012 (2013).
13. Boeckh M, Nichols WG. The impact of cytomegalovirus serostatus of donor and recipient before hematopoietic stem cell transplantation in the era of antiviral prophylaxis and preemptive therapy. Blood 103(6), 2003-2008 (2004).
14. Ljungman P, Perez-Bercoff L, Jonsson J et al. Risk factors for the development of cytomegalovirus disease after allogeneic stem cell transplantation. Haematologica 91(1), 78-83 (2006).
15. Ljungman P, Brand R, Einsele H, Frassoni F, Niederwieser D, Cordonnier C. Donor CMV serologic status and outcome of CMVseropositive recipients after unrelated donor stem cell transplantation: an EBMT megafile analysis. Blood 102(13), 4255-4260 (2003).
16. Ganepola S, Gentilini C, Hilbers U et al. Patients at high risk for CMV infection and disease show delayed CD8+ T-cell immune recovery after allogeneic stem cell transplantation. Bone Marrow Transplant. 39(5), 293-299 (2007).
17. Ljungman P, Brand R, Hoek J et al. Donor cytomegalovirus status influences the outcome of allogeneic stem cell transplant: a study by the European group for blood and marrow transplantation. Clin. Infect Dis. 59(4), 473-481 (2014).
18. Zhou W, Longmate J, Lacey SF et al. Impact of donor CMV status on viral infection and reconstitution of multifunction CMV-specific T cells in CMV-positive transplant recipients. Blood 113(25), 6465-6476 (2009).
19. Junghanss C, Boeckh M, Carter RA et al. Incidence and outcome of cytomegalovirus infections following nonmyeloablative compared with myeloablative allogeneic stem cell transplantation, a matched control study. Blood 99(6), 1978-1985 (2002).
20. Nakamae H, Kirby KA, Sandmaier BM et al. Effect of conditioning regimen intensity on CMV infection in allogeneic hematopoietic cell transplantation. Biol. Blood Marrow Transplant. 15(6), 694-703 (2009).
21. Loeffler J, Steffens M, Arlt EM et al. Polymorphisms in the genes encoding chemokine receptor 5, interleukin-10, and monocyte chemoattractant protein 1 contribute to cytomegalovirus reactivation and disease after allogeneic stem cell transplantation. J. Clin. Microbiol. 44(5), 1847-1850 (2006).
22. Mezger M, Steffens M, Semmler C et al. Investigation of promoter variations in dendritic cell-specific ICAM3-grabbing non-integrin (DC-SIGN) (CD209) and their relevance for human cytomegalovirus reactivation and disease after allogeneic stem-cell transplantation. Clin. Microbiol. Infect. 14(3), 228-234 (2008).
23. Ge D, Fellay J, Thompson AJ et al. Genetic variation in IL28B predicts hepatitis C treatment-induced viral clearance. Nature 461(7262), 399-401 (2009).
24. Corrales I, Gimenez E, Solano C et al. Incidence and dynamics of active cytomegalovirus infection in allogeneic stem cell transplant patients according to single nucleotide polymorphisms in donor and recipient CCR5, MCP-1, IL-10, and TLR9 genes. J. Med. Virol. 87(29), 248-255 (2015).
25. Bravo D, Solano C, Gimenez E et al. Effect of the IL28B Rs12979860 C/T polymorphism on the incidence and features of active cytomegalovirus infection in allogeneic stem cell transplant patients. J. Med. Virol. 86(5), 838-844 (2014).
26. Ljungman P, De La Camara R, Cordonnier C et al. Management of CMV, HHV-6, HHV-7 and Kaposi-sarcoma herpesvirus (HHV-8) infections in patients with hematological malignancies and after SCT. Bone Marrow Transplant. 42(4), 227-240 (2008).
27. Boeckh M, Ljungman P. How we treat cytomegalovirus in hematopoietic cell transplant recipients. Blood 113(23), 5711-5719 (2009).
28. Gerna G, Lilleri D, Caldera D, Furione M, Zenone Bragotti L, Alessandrino EP. Validation of a DNAemia cutoff for preemptive therapy of cytomegalovirus infection in adult hematopoietic stem cell transplant recipients. Bone Marrow Transplant. 41(10), 873-879 (2008).
29. Green ML, Leisenring W, Stachel D et al. Efficacy of a viral load-based, risk-adapted, preemptive treatment strategy for prevention of cytomegalovirus disease after hematopoietic cell transplantation. Biol. Blood Marrow Transplant. 18(11), 1687-99 (2012).
30. Gimeno C, Solano C, Latorre JC et al. Quantification of DNA in plasma by an automated real-time PCR assay (cytomegalovirus PCR kit) for surveillance of active cytomegalovirus infection and guidance of preemptive therapy for allogeneic hematopoietic stem cell transplant recipients. J. Clin. Microbiol. 46(10), 3311-3318 (2008).
31. Boeckh M, Huang M, Ferrenberg J et al. Optimization of quantitative detection of cytomegalovirus DNA in plasma by real-time PCR. J. Clin. Microbiol. 42(3), 1142-1148 (2004).
32. Griscelli F, Barrois M, Chauvin S, Lastere S, Bellet D, Bourhis JH. Quantification of human cytomegalovirus DNA in bone marrow transplant recipients by real-time PCR. J. Clin. Microbiol. 39(12), 4362-4369 (2001).
33. Harrington SM, Buller RS, Storch GA et al. The effect of quantification standards used in real-time CMV PCR assays on guidelines for initiation of therapy in allogeneic stem cell transplant patients. Bone Marrow Transplant. 39(4), 237-238 (2007).
34. Herrmann B, Larsson VC, Rubin CJ et al. Comparison of a duplex quantitative real-time PCR assay and the COBAS Amplicor CMV Monitor test for detection of cytomegalovirus. J. Clin. Microbiol. 42(5), 1909-1914 (2004).
35. Hong KM, Najjar H, Hawley M, Press RD. Quantitative real-time PCR with automated sample preparation for diagnosis and monitoring of cytomegalovirus infection in bone marrow transplant patients. Clin. Chem. 50(5), 846-856 (2004).
36. Kalpoe JS, Kroes AC, De Jong MD et al. Validation of clinical application of cytomegalovirus plasma DNA load measurement and definition of treatment criteria by analysis of correlation to antigen detection. J. Clin. Microbiol. 42(4), 1498-1504 (2004).
37. Leruez-Ville M, Ouachee M, Delarue R et al. Monitoring cytomegalovirus infection in adult and pediatric bone marrow transplant recipients by a real-time PCR assay performed with blood plasma. J. Clin. Microbiol. 41(5), 2040-2046 (2003).
38. Limaye AP, Huang ML, Leisenring W, Stensland L, Corey L, Boeckh M. Cytomegalovirus (CMV) DNA load in plasma for the diagnosis of CMV disease before engraftment in hematopoietic stem-cell transplant recipients. J. Infect. Dis. 183(3), 377-382 (2001).
39. Machida U, Kami M, Fukui T et al. Real-time automated PCR for early diagnosis and monitoring of cytomegalovirus infection after bone marrow transplantation. J. Clin. Microbiol. 38(7), 2536-2542 (2000).
40. Mori T, Okamoto S, Watanabe R et al. Dose-adjusted preemptive therapy for cytomegalovirus disease based on real-time polymerase chain reaction after allogeneic hematopoietic stem cell transplantation. Bone Marrow Transplant. 29(9), 777-782 (2002).
41. Nitsche A, Steuer N, Schmidt CA et al. Detection of human cytomegalovirus DNA by real-time quantitative PCR. J. Clin. Microbiol. 38(7), 2734-2737 (2000).
42. Pumannova M, Roubalova K, Vitek A, Sajdova J. Comparison of quantitative competitive polymerase chain reactionenzyme-linked immunosorbent assay with LightCycler-based polymerase chain reaction for measuring cytomegalovirus DNA in patients after hematopoietic stem cell transplantation. Diagn. Microbiol. Infect. Dis. 54(2), 115-120 (2006).
43. Ruell J, Barnes C, Mutton K et al. Active CMV disease does not always correlate with viral load detection. Bone Marrow Transplant. 40(1), 55-61 (2007).
44. Schaade L, Kockelkorn P, Ritter K, Kleines M. Detection of cytomegalovirus DNA in human specimens by LightCycler PCR. J. Clin. Microbiol. 38(11), 4006-4009 (2000).
45. Tanaka Y, Kanda Y, Kami M et al. Monitoring cytomegalovirus infection by antigenemia assay and two distinct plasma real-time PCR methods after hematopoietic stem cell transplantation. Bone Marrow Transplant. 30(5), 315-319 (2002).
46. Tanaka N, Kimura H, Iida K et al. Quantitative analysis of cytomegalovirus load using a real-time PCR assay. J. Med. Virol. 60(4), 455-462 (2000).
47. Caliendo AM, Ingersoll J, Fox-Canale AM et al. Evaluation of real-time PCR laboratory-developed tests using analytespecific reagents for cytomegalovirus quantification. J. Clin. Microbiol. 45(6), 1723-1727 (2007).
48. Gouarin S, Vabret A, Scieux C et al. Multicentric evaluation of a new commercial cytomegalovirus real-time PCR quantitation assay. J. Virol. Meth. 146(1-2), 147-154 (2007).
49. Hanson KE, Reller LB, Kurtzberg J, Horwitz M, Long G, Alexander BD. Comparison of the Digene Hybrid Capture System Cytomegalovirus (CMV) DNA (version 2.0), Roche CMV UL54 analytespecific reagent, and QIAGEN RealArt CMV LightCycler PCR reagent tests using AcroMetrix OptiQuant CMV DNA quantification panels and specimens from allogeneic-stem-cell transplant recipients. J. Clin. Microbiol. 45(6), 1972-1973 (2007).
50. Yerly S, Perrin L, Van Delden C et al. Cytomegalovirus quantification in plasma by an automated real-time PCR assay. J. Clin. Virol. 38(4), 298-303 (2007).
51. Allice T, Cerutti F, Pittaluga F et al. Evaluation of a novel real-time PCR system for cytomegalovirus DNA quantitation on whole blood and correlation with pp65-antigen test in guiding pre-emptive antiviral treatment. J. Virol. Meth. 148(1-2), 9-16 (2008).
52. Abbate I, Finnstrom N, Zaniratti S et al. Evaluation of an automated extraction system in combination with Affigene CMV Trender for CMV DNA quantitative determination: comparison with nested PCR and pp65 antigen test. J. Virol. Meth. 151(1), 61-65 (2008).
53. Michelin BD, Hadzisejdic I, Bozic M et al. Detection of cytomegalovirus (CMV) DNA in EDTA whole-blood samples: evaluation of the quantitative artus CMV LightCycler PCR kit in conjunction with automated sample preparation. J. Clin. Microbiol. 46(4), 1241-1245 (2008).
54. Vincent E, Gu Z, Morgenstern M, Gibson C, Pan J, Hayden RT. Detection of cytomegalovirus in whole blood using three different real-time PCR chemistries. J. Mol. Diagn. 11(1), 54-59 (2009).
55. Bravo D, Clari MA, Costa E et al. Comparative evaluation of three automated systems for DNA extraction in conjunction with three commercially available real-time PCR assays for quantitation of plasma Cytomegalovirus DNAemia in allogeneic stem cell transplant recipients. J. Clin. Microbiol. 49(8), 2899-2904 (2011).
56. Furione M, Rognoni V, Cabano E, Baldanti F. Kinetics of human cytomegalovirus (HCMV) DNAemia in transplanted patients expressed in international units as determined with the Abbott RealTime CMV assay and an in-house assay. J. Clin. Virol. 55(4), 317-322 (2012).
57. Clari MA, Bravo D, Costa E et al. Comparison of the new Abbott Real Time CMV assay and the Abbott CMV PCR Kit for the quantitation of plasma cytomegalovirus DNAemia. Diagn. Microbiol. Infect. Dis. 75(2), 207-209 (2013).
58. Hirsch HH, Lautenschlager I, Pinsky BA et al. An international multicenter performance analysis of cytomegalovirus load tests. Clin. infect. Dis. 56(3), 367-373 (2013).
59. Pang XL, Fox JD, Fenton JM, Miller GG, Caliendo AM, Preiksaitis JK. Interlaboratory comparison of cytomegalovirus viral load assays. Am. J. Transplant. 9(2), 258-268 (2009).
60. Wolff DJ, Heaney DL, Neuwald PD, Stellrecht KA, Press RD. Multi-Site PCR-based CMV viral load assessment-assays demonstrate linearity and precision, but lack numeric standardization: a report of the association for molecular pathology. J. Mol. Diagn. 11(2), 87-92 (2009).
61. Gracia-Ahufinger I, Tormo N, Espigado I et al. Differences in cytomegalovirus plasma viral loads measured in allogeneic hematopoietic stem cell transplant recipients using two commercial real-time PCR assays. J. Clin. Virol. 48(2), 142-146 (2010).
62. Fryer JF, Heath AB, Anderson R, Minor PD, the Collaborative Study Group. Collaborative Study to Evaluate the Proposed 1st WHO International Standard for Human Cytomegalovirus (HCMV) for Nucleic Acid Amplification (NAT)-Based Assays (WHO/BS/10.2138) (2010). www.who.int/iris/handle/10665/70521
63. Clari MA, Bravo D, Costa E et al. Comparison of the new Abbott Real Time CMV assay and the Abbott CMV PCR Kit for the quantitation of plasma cytomegalovirus DNAemia. Diagn. Microbiol. Infect. Dis. 75(2), 207-209 (2013).
64. Hayden RT, Yan X, Wick MT et al. Factors contributing to variability of quantitative viral PCR results in proficiency testing samples: a multivariate analysis. J. Clin. Microbiol. 50(2), 337-345 (2012).
65. Caliendo AM. The long road toward standardization of viral load testing for cytomegalovirus. Clin. Iinfect. Dis. 56(3), 374-375 (2013).
66. Kraft CS, Armstrong WS, Caliendo AM. Interpreting quantitative cytomegalovirus DNA testing: understanding the laboratory perspective. Clin. Infect. Dis. 54(12), 1793-1797 (2012).
67. Hayden RT, Shahbazian MD, Valsamakis A et al. Multicenter evaluation of a commercial cytomegalovirus quantitative standard: effects of commutability on interlaboratory concordance. J. Clin. Microbiol. 51(11), 3811-3817 (2013).
68. Solano C, Navarro D. Clinical virology of cytomegalovirus infection following hematopoietic transplantation. Future Virol. 5(1), 111-124 (2010).
69. Garrigue I, Doussau A, Asselineau J et al. Prediction of cytomegalovirus (CMV) plasma load from evaluation of CMV whole-blood load in samples from renal transplant recipients. J. Clin. Microbiol. 46(2), 493-498 (2008).
70. Gurtler V, Mayall BC, Wang J, Ghaly-Derias S. The increased sensitivity of human cytomegalovirus (HCMV) PCR quantitation in whole blood affects reproductive rate (Ro) measurement. J. Virol. Meth. 196, 179-184 (2014).
71. Xie L, Liang XN, Deng Y et al. Effects of storage time on Cytomegalovirus DNA stability in plasma determined by quantitative real-time PCR. J. Virol. Meth. 207, 196-199 (2014).
72. Atkinson C, Emery VC. Cytomegalovirus quantification: where to next in optimising patient management? J. Clin. Virol. 51(4), 223-228 (2011).
73. Andrews PA, Emery VC, Newstead C. Summary of the British Transplantation Society Guidelines for the Prevention and Management of CMV disease after solid organ transplantation. Transplantation 92(11), 1181-1187 (2011).
74. Emery VC, Sabin CA, Cope AV, Gor D, Hassan-Walker AF, Griffiths PD. Application of viral-load kinetics to identify patients who develop cytomegalovirus disease after transplantation. Lancet 355(9220), 2032-2036 (2000).
75. Stachel D, Kirby K, Corey L, Boeckh M. CMV Viral load as predictor for transplant-related mortality in the era of pre-emptive therapy. Bone Marrow Transplant. 41(Suppl.), S46 (2008).
76. Gimenez E, Munoz-Cobo B, Solano C, Amat P, Navarro D. Early kinetics of plasma cytomegalovirus DNA load in allogeneic stem cell transplant recipients in the era of highly sensitive real-time PCR assays: does it have any clinical value? J. Clin. Microbiol. 52(2), 654-656 (2014).
77. Nichols WG, Corey L, Gooley T et al. Rising pp65 antigenemia during preemptive anticytomegalovirus therapy after allogeneic hematopoietic stem cell transplantation: risk factors, correlation with DNA load, and outcomes. Blood 97(4), 867-874 (2001).
78. Gerna G, Lilleri D, Zecca M et al. Rising antigenemia levels may be misleading in pre-emptive therapy of human cytomegalovirus infection in allogeneic hematopoietic stem cell transplant recipients. Haematologica 90(4), 526-533 (2005).
79. Tormo N, Solano C, Benet I et al. Lack of prompt expansion of cytomegalovirus pp65 and IE-1-specific IFNgamma CD8+ and CD4+ T cells is associated with rising levels of pp65 antigenemia and DNAemia during pre-emptive therapy in allogeneic hematopoietic stem cell transplant recipients. Bone Marrow Transplant. 45(3), 543-549 (2010).
80. Buyck HC, Griffiths PD, Emery VC. Human cytomegalovirus (HCMV) replication kinetics in stem cell transplant recipients following anti-HCMV therapy. J. Clin. Virol. 49(1), 32-36 (2010).
81. Munoz-Cobo B, Solano C, Costa E et al. Dynamics of cytomegalovirus (CMV) plasma DNAemia in initial and recurrent episodes of active CMV infection in the allogeneic stem cell transplantation setting: implications for designing preemptive antiviral therapy strategies. Biol. Blood Marrow Transplant. 17(11), 1602-1611 (2011).
82. Li CR, Greenberg PD, Gilbert MJ, Goodrich JM, Riddell SR. Recovery of HLA-restricted cytomegalovirus (CMV)-specific T-cell responses after allogeneic bone marrow transplant: correlation with CMV disease and effect of ganciclovir prophylaxis. Blood 83(7), 1971-1979 (1994).
83. Quinnan GV Jr, Kirmani N, Rook AH et al. Cytotoxic t cells in cytomegalovirus infection: HLA-restricted T-lymphocyte and non-Tlymphocyte cytotoxic responses correlate with recovery from cytomegalovirus infection in bone-marrow-transplant recipients. N. Engl. J. Med. 307(1), 7-13 (1982).
84. Reusser P, Riddell SR, Meyers JD, Greenberg PD. Cytotoxic T-lymphocyte response to cytomegalovirus after human allogeneic bone marrow transplantation: pattern of recovery and correlation with cytomegalovirus infection and disease. Blood 78(5), 1373-1380 (1991).
85. Riddell SR, Watanabe KS, Goodrich JM, Li CR, Agha ME, Greenberg PD. Restoration of viral immunity in immunodeficient humans by the adoptive transfer of T-cell clones. Science 257(5067), 238-241 (1992).
86. Hakki M, Riddell SR, Storek J et al. Immune reconstitution to cytomegalovirus after allogeneic hematopoietic stem cell transplantation: impact of host factors, drug therapy, and subclinical reactivation. Blood 102(8), 3060-3067 (2003).
87. Ozdemir E, St John LS, Gillespie G et al. Cytomegalovirus reactivation following allogeneic stem cell transplantation is associated with the presence of dysfunctional antigen-specific CD8+ T cells. Blood 100(10), 3690-3697 (2002).
88. Aubert G, Hassan-Walker AF, Madrigal JA et al. Cytomegalovirus-specific cellular immune responses and viremia in recipients of allogeneic stem cell transplants. J. Infect. Dis. 184(8), 955-963 (2001).
89. Cwynarski K, Ainsworth J, Cobbold M et al. Direct visualization of cytomegalovirusspecific T-cell reconstitution after allogeneic stem cell transplantation. Blood 97(5), 1232-1240 (2001).
90. Solano C, Benet I, Clari MA et al. Enumeration of cytomegalovirus-specific interferongamma CD8+ and CD4+ T cells early after allogeneic stem cell transplantation may identify patients at risk of active cytomegalovirus infection. Haematologica 93(9), 1434-1436 (2008).
91. Sylwester AW, Mitchell BL, Edgar JB et al. Broadly targeted human cytomegalovirusspecific CD4+ and CD8+ T cells dominate the memory compartments of exposed subjects. J. Exp. Med. 202(5), 673-685 (2005).
92. Einsele H, Roosnek E, Rufer N et al. Infusion of cytomegalovirus (CMV)-specific T cells for the treatment of CMV infection not responding to antiviral chemotherapy. Blood 99(11), 3916-3922 (2002).
93. Krol L, Stuchly J, Hubacek P et al. Signature profiles of CMV-specific T-cells in patients with CMV reactivation after hematopoietic SCT. Bone Marrow Transplant. 46(8), 1089-1098 (2011).
94. Lacey SF, La Rosa C, Zhou W et al. Functional comparison of T cells recognizing cytomegalovirus pp65 and intermediate-early antigen polypeptides in hematopoietic stem-cell transplant and solid organ transplant recipients. J. Infect. Dis. 194(10), 1410-1421 (2006).
95. Lilleri D, Fornara C, Chiesa A, Caldera D, Alessandrino EP, Gerna G. Human cytomegalovirus-specific CD4+ and CD8+ T-cell reconstitution in adult allogeneic hematopoietic stem cell transplant recipients and immune control of viral infection. Haematologica 93(2), 248-256 (2008).
96. Makedonas G, Hutnick N, Haney D et al. Perforin and IL-2 upregulation define qualitative differences among highly functional virus-specific human CD8 T cells. PLoS Pathog. 6(3), e1000798 (2010).
97. Nebbia G, Mattes FM, Smith C et al. Polyfunctional cytomegalovirus-specific CD4+ and pp65 CD8+ T cells protect against high-level replication after liver transplantation. Am. J. Transplant. 8(12), 2590-2599 (2008).
98. Lachmann R, Bajwa M, Vita S et al. Polyfunctional T cells accumulate in large human cytomegalovirus-specific T cell responses. J. Virol. 86(2), 1001-1009 (2012).
99. Munoz-Cobo B, Solano C, Benet I et al. Functional profile of cytomegalovirus (CMV)-specific CD8+ T cells and kinetics of NKG2C+ NK cells associated with the resolution of CMV DNAemia in allogeneic stem cell transplant recipients. J. Med. Virol. 84(2), 259-267 (2012).
100. Espigado I, De La Cruz-Vicente F, Benmarzouk-Hidalgo OJ et al. Timing of CMV-specific effector memory T-cells predicts viral replication and Survival after allogeneic hematopoietic stem cell transplantation. Transpl. Int. doi:10.1111/tri.12406 (2014) (Epub ahead of print).
101. Barron MA, Gao D, Springer KL et al. Relationship of reconstituted adaptive and innate cytomegalovirus (CMV)-specific immune responses with CMV viremia in hematopoietic stem cell transplant recipients. Clin. Iinfect. Dis. 49(12), 1777-1783 (2009).
102. Foley B, Cooley S, Verneris MR et al. Cytomegalovirus reactivation after allogeneic transplantation promotes a lasting increase in educated NKG2C+ natural killer cells with potent function. Blood 119(11), 2665-2674 (2012).
103. Kuijpers TW, Baars PA, Dantin C, Van Den Burg M, Van Lier RA, Roosnek E. Human NK cells can control CMV infection in the absence of T cells. Blood 112(3), 914-915 (2008).
104. Lopez-Verges S, Milush JM, Schwartz BS et al. Expansion of a unique CD57(+) NKG2Chi natural killer cell subset during acute human cytomegalovirus infection. Proc. Natl Acad. Sci. USA 108(36), 14725-14732 (2011).
105. Kheav VD, Busson M, Scieux C et al. Favorable impact of natural killer cell reconstitution on chronic graft-versus-host disease and cytomegalovirus reactivation after allogeneic hematopoietic stem cell transplantation. Haematologica doi:10.3324/haematol.2014.108407 (2014) (Epub ahead of print).
106. Fouts AE, Chan P, Stephan JP, Vandlen R, Feierbach B. Antibodies against the gH/gL/UL128/UL130/UL131 complex comprise the majority of the anticytomegalovirus (anti-CMV) neutralizing antibody response in CMV hyperimmune globulin. J. Virol. 86(13), 7444-7447 (2012).
107. Genini E, Percivalle E, Sarasini A, Revello MG, Baldanti F, Gerna G. Serum antibody response to the gH/gL/pUL128-131 five-protein complex of human cytomegalovirus (HCMV) in primary and reactivated HCMV infections. J. Clin. Virol. 52(2), 113-118 (2011).
108. Lilleri D, Kabanova A, Lanzavecchia A, Gerna G. Antibodies against neutralization epitopes of human cytomegalovirus gH/gL/pUL128-130-131 complex and virus spreading may correlate with virus control in vivo. J. Clin. Immunol. 32(6), 1324-1331 (2012).
109. Munoz I, Gutierrez A, Gimeno C et al. Lack of association between the kinetics of human cytomegalovirus (HCMV) glycoprotein B (gB)-specific and neutralizing serum antibodies and development or recovery from HCMV active infection in patients undergoing allogeneic stem cell transplant. J. Med. Virol. 65(1), 77-84 (2001).
110. Crough T, Khanna R. Immunobiology of human cytomegalovirus: from bench to bedside. Clin. Microbiol. Rev. 22(1), 76-98 (2009).
111. Kharfan-Dabaja MA, Boeckh M, Wilck MB et al. A novel therapeutic cytomegalovirus DNA vaccine in allogeneic haemopoietic stem-cell transplantation: a randomised, double-blind, placebo-controlled, Phase 2 trial. Lancet Infect. Dis. 12(4), 290-299 (2012).
112. Ljungman P. Would monitoring CMV immune responses allow improved control of CMV in stem cell transplant patients. J. Clin. Virol. 35(4), 493-495 (2006).
113. Baldanti F, Lilleri D, Gerna G. Monitoring human cytomegalovirus infection in transplant recipients. J. Clin. Virol. 41(3), 237-241 (2008).
114. Egli A, Humar A, Kumar D. State-of-the-art monitoring of cytomegalovirus-specific cell-mediated immunity after organ transplant: a primer for the clinician. Clin. Infect. Dis. 55(12), 1678-1689 (2012).
115. Li Pira G, Kern F, Gratama J, Roederer M, Manca F. Measurement of antigen specific immune responses: 2006 update. Cytometry B Clin. Cytom. 72(2), 77-85 (2007).
116. Lilleri D, Gerna G, Fornara C, Lozza L, Maccario R, Locatelli F. Prospective simultaneous quantification of human cytomegalovirus-specific CD4+ and CD8+ T-cell reconstitution in young recipients of allogeneic hematopoietic stem cell transplants. Blood 108(4), 1406-1412 (2006).
117. Moins-Teisserenc H, Busson M, Scieux C et al. Patterns of cytomegalovirus reactivation are associated with distinct evolutive profiles of immune reconstitution after allogeneic hematopoietic stem cell transplantation. J. Infect. Dis. 198(6), 818-826 (2008).
118. Tormo N, Solano C, Benet I et al. Kinetics of cytomegalovirus (CMV) pp65 and IE-1-specific IFNgamma CD8+ and CD4+ T cells during episodes of viral DNAemia in allogeneic stem cell transplant recipients: potential implications for the management of active CMV infection. J. Med. Virol. 82(7), 1208-1215 (2010).
119. Tormo N, Solano C, Benet I et al. Reconstitution of CMV pp65 and IE-1-specific IFN-gamma CD8(+) and CD4(+) T-cell responses affording protection from CMV DNAemia following allogeneic hematopoietic SCT. Bone Marrow Transplant. 46(11), 1437-1443 (2011).
120. Pourgheysari B, Piper KP, Mclarnon A et al. Early reconstitution of effector memory CD4+ CMV-specific T cells protects against CMV reactivation following allogeneic SCT. Bone Marrow Transplant. 43(11), 853-861 (2009).
121. Foster AE, Gottlieb DJ, Sartor M, Hertzberg MS, Bradstock KF. Cytomegalovirus-specific CD4+ and CD8+ T-cells follow a similar reconstitution pattern after allogeneic stem cell transplantation. Biol. Blood Marrow Transplant. 8(9), 501-511 (2002).
122. Gallez-Hawkins G, Thao L, Lacey SF et al. Cytomegalovirus immune reconstitution occurs in recipients of allogeneic hematopoietic cell transplants irrespective of detectable cytomegalovirus infection. Biol. Blood Marrow Transplant. 11(11), 890-902 (2005).
123. Lilleri D, Gerna G, Zelini P et al. Monitoring of human cytomegalovirus and virus-specific T-cell response in young patients receiving allogeneic hematopoietic stem cell transplantation. PLoS ONE 7(7), e41648 (2012).
124. Ohnishi M, Sakurai T, Heike Y et al. Evaluation of cytomegalovirus-specific T-cell reconstitution in patients after various allogeneic haematopoietic stem cell transplantation using interferon-gammaenzyme-linked immunospot and human leucocyte antigen tetramer assays with an immunodominant T-cell epitope. Br. J. Haematol. 131(4), 472-479 (2005).
125. Hebart H, Daginik S, Stevanovic S et al. Sensitive detection of human cytomegalovirus peptide-specific cytotoxic T-lymphocyte responses by interferon-gamma-enzymelinked immunospot assay and flow cytometry in healthy individuals and in patients after allogeneic stem cell transplantation. Blood 99(10), 3830-3837 (2002).
126. Gimenez E, Solano C, Azanza JR, Amat P, Navarro D. Monitoring of trough plasma ganciclovir levels and peripheral blood cytomegalovirus (CMV)-specific CD8+ T cells to predict CMV DNAemia clearance in preemptively treated allogeneic stem cell transplant recipients. Antimicrob. Agents Chemother. 58(9), 5602-5605 (2014).
127. Borchers S, Bremm M, Lehrnbecher T et al. Sequential anti-cytomegalovirus response monitoring may allow prediction of cytomegalovirus reactivation after allogeneic stem cell transplantation. PLoS ONE 7(12), e50248 (2012).
128. Walker S, Fazou C, Crough T et al. Ex vivo monitoring of human cytomegalovirusspecific CD8+ T-cell responses using QuantiFERON-CMV. Transpl. Infect. Dis. 9(2), 165-170 (2007).
129. Fleming T, Dunne J, Crowley B. Ex vivo monitoring of human cytomegalovirusspecific CD8(+) T-Cell responses using the QuantiFERON-CMV assay in allogeneic hematopoietic stem cell transplant recipients attending an Irish hospital. J. Med. Virol. 82(3), 433-440 (2010).
130. Clari MA, Munoz-Cobo B, Solano C et al. Performance of the QuantiFERONcytomegalovirus (CMV) assay for detection and estimation of the magnitude and functionality of the CMV-specific gamma interferon-producing CD8(+) T-cell response in allogeneic stem cell transplant recipients. Clin. Vaccine Immunol. 19(5), 791-796 (2012).
131. Tey SK, Kennedy GA, Cromer D et al. Clinical assessment of anti-viral CD8+ T cell immune monitoring using QuantiFERONCMV( R) assay to identify high risk allogeneic hematopoietic stem cell transplant patients with CMV infection complications. PLoS ONE 8(10), e74744 (2013).
132. Borchers S, Bremm M, Lehrnbecher T et al. Sequential anti-cytomegalovirus response monitoring may allow prediction of cytomegalovirus reactivation after allogeneic stem cell transplantation. PLoS ONE 7(12), e50248 (2012).
133. Gratama JW, Boeckh M, Nakamura R et al. Immune monitoring with iTAg MHC Tetramers for prediction of recurrent or persistent cytomegalovirus infection or disease in allogeneic hematopoietic stem cell transplant recipients: a prospective multicenter study. Blood 116(10), 1655-1662 (2010).
134. Koehl U, Dirkwinkel E, Koenig M et al. Reconstitution of cytomegalovirus specific T cells after pediatric allogeneic stem cell transplantation: results from a pilot study using a multi-allele CMV tetramer group. Klin. Padiatr. 220(6), 348-352 (2008).
135. Gratama JW, Cornelissen JJ. Clinical utility of tetramer-based immune monitoring in allogeneic stem cell transplantation. BioDrugs 17(5), 325-338 (2003).
136. De Paolis P, Favaro A, Piola A et al. "Immuknow" to measurement of cellmediated immunity in renal transplant recipients undergoing short-term evaluation. Transplant. Proc. 43(4), 1013-1016 (2011).
137. Ge S, Pao A, Vo A et al. Immunologic parameters and viral infections in patients desensitized with intravenous immunoglobulin and rituximab. Transpl. Immunol. 24(3), 142-148 (2011).
138. Husain S, Raza K, Pilewski JM et al. Experience with immune monitoring in lung transplant recipients: correlation of low immune function with infection. Transplantation 87(12), 1852-1857 (2009).
139. Mizuno S, Nakatani K, Muraki Y et al. Combination assays for evaluation of immune function and CYP3A5 genotype to identify the risk of infectious complications and mortality in living donor liver transplant patients. Ann. Transplant. 18, 349-357 (2013).
140. Nishikawa K, Mizuno S, Masui S et al. Usefulness of monitoring cell-mediated immunity for predicting post-kidney transplantation viral infection. Transplant. Proc. 46(2), 552-555 (2014).
141. Zeevi A, Husain S, Spichty KJ et al. Recovery of functional memory T cells in lung transplant recipients following induction therapy with alemtuzumab. Am. J. Transplant. 7(2), 471-475 (2007).
142. Avetisyan G, Aschan J, Hagglund H, Ringden O, Ljungman P. Evaluation of intervention strategy based on CMV-specific immune responses after allogeneic SCT. Bone Marrow Transplant. 40(9), 865-869 (2007).
143. Solano C, Benet I, Remigia MJ et al. Immunological monitoring for guidance of preemptive antiviral therapy for active cytomegalovirus infection in allogeneic stem-cell transplant recipients: a pilot experience. Transplantation 92(4), e17-e20 (2011).
144. Eid AJ, Razonable RR. New developments in the management of cytomegalovirus infection after solid organ transplantation. Drugs 70(8), 965-981 (2010).
145. Emery VC, Griffiths PD. Prediction of cytomegalovirus load and resistance patterns after antiviral chemotherapy. Proc. Natl Acad. Sci. USA 97(14), 8039-8044 (2000).
146. Torres-Madriz G, Boucher HW. Immunocompromised hosts: perspectives in the treatment and prophylaxis of cytomegalovirus disease in solid-organ transplant recipients. Clin. Infect. Dis. 47(5), 702-711 (2008).
147. Lurain NS, Chou S. Antiviral drug resistance of human cytomegalovirus. Clin. Microbiol. Rev. 23(4), 689-712 (2010).
148. Strasfeld L, Chou S. Antiviral drug resistance: mechanisms and clinical implications. Infect. Dis. Clin. North Am. 24(2), 413-437 (2010).
149. Drew WL, Miner RC, Marousek GI, Chou S. Maribavir sensitivity of cytomegalovirus isolates resistant to ganciclovir, cidofovir or foscarnet. J. Clin. Virol. 37(2), 124-127 (2006).
150. Winston DJ, Young JA, Pullarkat V et al. Maribavir prophylaxis for prevention of cytomegalovirus infection in allogeneic stem cell transplant recipients: a multicenter, randomized, double-blind, placebocontrolled, dose-ranging study. Blood 111(11), 5403-5410 (2008).
151. Marty FM, Ljungman P, Papanicolaou GA et al. Maribavir prophylaxis for prevention of cytomegalovirus disease in recipients of allogeneic stem-cell transplants: a Phase 3, double-blind, placebo-controlled, randomised trial. Lancet Infect. Dis. 11(4), 284-292 (2011).
152. Winston DJ, Saliba F, Blumberg E et al. Efficacy and safety of maribavir dosed at 100 mg orally twice daily for the prevention of cytomegalovirus disease in liver transplant recipients: a randomized, double-blind, multicenter controlled trial. Am. J. Transplant. 12(11), 3021-3030 (2012).
153. Webel R, Hakki M, Prichard MN, Rawlinson WD, Marschall M, Chou S. Differential properties of cytomegalovirus pUL97 kinase isoforms affect viral replication and maribavir susceptibility. J. Virol. 88(9), 4776-4785 (2014).
154. Avery RK, Marty FM, Strasfeld L et al. Oral maribavir for treatment of refractory or resistant cytomegalovirus infections in transplant recipients. Transpl. Infect. Dis. 12(6), 489-496 (2010).
155. Beadle JR, Hartline C, Aldern KA et al. Alkoxyalkyl esters of cidofovir and cyclic cidofovir exhibit multiple-log enhancement of antiviral activity against cytomegalovirus and herpesvirus replication in vitro. Antimicrob. Agents Chemother. 46(8), 2381-2386 (2002).
156. Dropulic LK, Cohen JI. Update on new antivirals under development for the treatment of double-stranded DNA virus infections. Clin. Pharmacol. Ther. 88(5), 610-619 (2010).
157. Marty FM, Winston DJ, Rowley SD et al. CMX001 to prevent cytomegalovirus disease in hematopoietic-cell transplantation. N. Engl. J. Med. 369(13), 1227-1236 (2013).
158. He R, Park K, Cai H et al. Artemisininderived dimer diphenyl phosphate is an irreversible inhibitor of human cytomegalovirus replication. Antimicrob. Agents Chemother. 56(7), 3508-3515 (2012).
159. Lau PK, Woods ML, Ratanjee SK, John GT. Artesunate is ineffective in controlling valganciclovir-resistant cytomegalovirus infection. Clin. Infect. Dis. 52(2), 279 (2011).
160. Shapira MY, Resnick IB, Chou S et al. Artesunate as a potent antiviral agent in a patient with late drug-resistant cytomegalovirus infection after hematopoietic stem cell transplantation. Clin. Infect. Dis. 46(9), 1455-1457 (2008).
161. Wolf DG, Shimoni A, Resnick IB et al. Human cytomegalovirus kinetics following institution of artesunate after hematopoietic stem cell transplantation. Antiviral. Res. 90(3), 183-186 (2011).
162. Goldner T, Hewlett G, Ettischer N, Ruebsamen-Schaeff H, Zimmermann H, Lischka P. The novel anticytomegalovirus compound AIC246 (Letermovir) inhibits human cytomegalovirus replication through a specific antiviral mechanism that involves the viral terminase. J. Virol. 85(20), 10884-10893 (2011).
163. Lischka P, Hewlett G, Wunberg T et al. In vitro and in vivo activities of the novel anticytomegalovirus compound AIC246. Antimicrob. Agents Chemother. 54(3), 1290-1297 (2010).
164. Verghese PS, Schleiss MR. Letermovir treatment of human cytomegalovirus infection antiinfective agent. Drugs Future 38(5), 291-298 (2013).
165. Chemaly RF, Ullmann AJ, Stoelben S et al. Letermovir for cytomegalovirus prophylaxis in hematopoietic-cell transplantation. N. Engl. J. Med. 370(19), 1781-1789 (2014).
166. Gentry BG, Drach JC. Metabolism of cyclopropavir and ganciclovir in human cytomegalovirus-infected cells. Antimicrob. Agents Chemother. 58(4), 2329-2333 (2014).
167. Gentry BG, Vollmer LE, Hall ED et al. Resistance of human cytomegalovirus to cyclopropavir maps to a base pair deletion in the open reading frame of UL97. Antimicrob. Agents Chemother. 57(9), 4343-4348 (2013).
168. Kern ER, Bidanset DJ, Hartline CB, Yan Z, Zemlicka J, Quenelle DC. Oral activity of a methylenecyclopropane analog, cyclopropavir, in animal models for cytomegalovirus infections. Antimicrob. Agents Chemother. 48(12), 4745-4753 (2004).
169. Chou S, Bowlin TL. Cytomegalovirus UL97 mutations affecting cyclopropavir and ganciclovir susceptibility. Antimicrob. Agents Chemother. 55(1), 382-384 (2011).
170. Waldman WJ, Knight DA, Lurain NS et al. Novel mechanism of inhibition of cytomegalovirus by the experimental immunosuppressive agent leflunomide. Transplantation 68(6), 814-825 (1999).
171. John GT, Manivannan J, Chandy S, Peter S, Jacob CK. Leflunomide therapy for cytomegalovirus disease in renal allograft recepients. Transplantation 77(9), 1460-1461 (2004).
172. Avery RK, Bolwell BJ, Yen-Lieberman B et al. Use of leflunomide in an allogeneic bone marrow transplant recipient with refractory cytomegalovirus infection. Bone Marrow Transplant. 34(12), 1071-1075 (2004).
173. Battiwalla M, Paplham P, Almyroudis NG et al. Leflunomide failure to control recurrent cytomegalovirus infection in the setting of renal failure after allogeneic stem cell transplantation. Transpl. Infect. Dis. 9(1), 28-32 (2007).
174. Verkaik NJ, Hoek RA, Van Bergeijk H et al. Leflunomide as part of the treatment for multidrug-resistant cytomegalovirus disease after lung transplantation: case report and review of the literature. Transpl. Infect. Dis. 15(6), E243-249 (2013).
175. Stevenson M. Therapeutic potential of RNA interference. N. Engl. J. Med. 351(17), 1772-1777 (2004).
176. Bai Z, Li L, Wang B et al. Inhibition of human cytomegalovirus infection by IE86-specific short hairpin RNA-mediated RNA interference. Biosci. Biotechnol. Biochem. 74(7), 1368-1372 (2010).
177. Dittmer A, Bogner E. Specific short hairpin RNA-mediated inhibition of viral DNA packaging of human cytomegalovirus. FEBS Lett. 580(26), 6132-6138 (2006).
178. Duan QJ, Tao R, Hu MF, Shang SQ. Efficient inhibition of human cytomegalovirus UL122 gene expression in cell by small interfering RNAs. J. Basic. Microbiol. 49(6), 531-537 (2009).
179. Reich SJ, Fosnot J, Kuroki A et al. Small interfering RNA (siRNA) targeting VEGF effectively inhibits ocular neovascularization in a mouse model. Mol. Vis. 9, 210-216 (2003).
180. De Fougerolles A, Vornlocher HP, Maraganore J, Lieberman J. Interfering with disease: a progress report on siRNA-based therapeutics. Nat. Rev. Drug Discov. 6(6), 443-453 (2007).
181. MK-8228 (Letermovir) versus placebo in the prevention of clinically-significant cytomegalovirus (CMV) infection in adult, CMV-seropositive allogeneic hematopoietic stem cell transplant recipients (MK-8228-001). https://clinicaltrials.gov/ct2/show
182. Anderson KP, Fox MC, Brown-Driver V, Martin MJ, Azad RF. Inhibition of human cytomegalovirus immediate-early gene expression by an antisense oligonucleotide complementary to immediate-early RNA. Antimicrob. Agents Chemother. 40(9), 2004-2011 (1996).
183. Mulamba GB, Hu A, Azad RF, Anderson KP, Coen DM. Human cytomegalovirus mutant with sequence-dependent resistance to the phosphorothioate oligonucleotide fomivirsen (ISIS 2922). Antimicrob. Agents Chemother. 42(4), 971-973 (1998).
184. Devi GR. siRNA-based approaches in cancer therapy. Cancer Gene Ther. 13(9), 819-829 (2006).
185. Hamilton ST, Milbradt J, Marschall M, Rawlinson WD. Human cytomegalovirus replication is strictly inhibited by siRNAs targeting UL54, UL97 or UL122/123 gene transcripts. PLoS ONE 9(6), e97231 (2014).
186. Peggs KS, Thomson K, Samuel E et al. Directly selected cytomegalovirus-reactive donor T cells confer rapid and safe systemic reconstitution of virus-specific immunity following stem cell transplantation. Clin. Infect. Dis. 52(1), 49-57 (2011).
187. Blyth E, Clancy L, Simms R et al. Donorderived CMV-specific T cells reduce the requirement for CMV-directed pharmacotherapy after allogeneic stem cell transplantation. Blood 121(18), 3745-3758 (2013).
188. Cobbold M, Khan N, Pourgheysari B et al. Adoptive transfer of cytomegalovirus-specific CTL to stem cell transplant patients after selection by HLA-peptide tetramers. J. Exp. Med. 202(3), 379-386 (2005).
189. Feuchtinger T, Opherk K, Bethge WA et al. Adoptive transfer of pp65-specific T cells for the treatment of chemorefractory cytomegalovirus disease or reactivation after haploidentical and matched unrelated stem cell transplantation. Blood 116(20), 4360-4367 (2010).
190. Stemberger C, Graef P, Odendahl M et al. Lowest numbers of primary CD8(+) T cells can reconstitute protective immunity upon adoptive immunotherapy. Blood 124(4), 628-637 (2014).
191. Preventative/preemptive adoptive transfer of peptide stimulated CMV/EBV specific T-cells in patients after allogeneic stem cell transplantation. https://clinicaltrials.gov/ct2/show
192. T-lymphocyte infusion or standard therapy in treating patients at risk of Cytomegalovirus infection after a donor stem cell transplant. https://clinicaltrials.gov/ct2/show
193. Stratton K. Vaccines for the 21st Century: a Tool for Decision Making. National Academy Press, Washington, DC, USA, (2000).
194. Schleiss MR, Heineman TC. Progress toward an elusive goal: current status of cytomegalovirus vaccines. Expert. Rev. Vaccines 4(3), 381-406 (2005).
195. Adler SP. Human CMV vaccine trials: what if CMV caused a rash? J. Clin. Virol. 41(3), 231-236 (2008).
196. Rieder F, Steininger C. Cytomegalovirus vaccine: Phase II clinical trial results. Clin. Microbiol. Infect. 20(Suppl. 5), 95-102 (2013).
197. A study to evaluate safety and tolerability of a therapeutic vaccine, ASP0113, in subjects undergoing allogeneic hematopoietic cell transplant. www.clinicaltrial.gov/ct2/show
198. Accelerated immunization to induce Cytomegalovirus immunity in stem cell donors. https://clinicaltrials.gov/ct2/show
199. Elek SD, Stern H. Development of a vaccine against mental retardation caused by cytomegalovirus infection in utero. Lancet 1(7845), 1-5 (1974).
200. Plotkin SA, Farquhar J, Horberger E. Clinical trials of immunization with the Towne 125 strain of human cytomegalovirus. J. Infect. Dis. 134(5), 470-475 (1976).
201. Heineman TC, Schleiss M, Bernstein DI et al. A Phase 1 study of 4 live, recombinant human cytomegalovirus Towne/Toledo chimeric vaccines. J. Infect. Dis. 193(10), 1350-1360 (2006).
202. Mitchell DK, Holmes SJ, Burke RL, Duliege AM, Adler SP. Immunogenicity of a recombinant human cytomegalovirus gB vaccine in seronegative toddlers. Pediatr. Infect. Dis. J. 21(2), 133-138 (2002).
203. Spaete RR, Saxena A, Scott PI et al. Sequence requirements for proteolytic processing of glycoprotein B of human cytomegalovirus strain Towne. J. Virol. 64(6), 2922-2931 (1990).
204. Sabbaj S, Pass RF, Goepfert PA, Pichon S. Glycoprotein B vaccine is capable of boosting both antibody and CD4 T-cell responses to cytomegalovirus in chronically infected women. J. Infect. Dis. 203(11), 1534-1541 (2011).
205. Pass RF, Zhang C, Evans A et al. Vaccine prevention of maternal cytomegalovirus infection. N. Engl. J. Med. 360(12), 1191-1199 (2009).
206. Griffiths PD, Stanton A, Mccarrell E et al. Cytomegalovirus glycoprotein-B vaccine with MF59 adjuvant in transplant recipients: a Phase 2 randomised placebocontrolled trial. Lancet 377(9773), 1256-1263 (2011).
207. Selinsky C, Luke C, Wloch M et al. A DNA-based vaccine for the prevention of human cytomegalovirus-associated diseases. Hum. Vaccin. 1(1), 16-23 (2005).
208. Wloch MK, Smith LR, Boutsaboualoy S et al. Safety and immunogenicity of a bivalent cytomegalovirus DNA vaccine in healthy adult subjects. J. Infect. Dis. 197(12), 1634-1642 (2008).
209. Liu MA, Ulmer JB. Human clinical trials of plasmid DNA vaccines. Adv. Genet. 55, 25-40 (2005).
210. La Rosa C, Longmate J, Lacey SF et al. Clinical evaluation of safety and immunogenicity of PADRE-cytomegalovirus (CMV) and tetanus-CMV fusion peptide vaccines with or without PF03512676 adjuvant. J. Infect. Dis. 205(8), 1294-1304 (2012).
211. Reap EA, Morris J, Dryga SA et al. Development and preclinical evaluation of an alphavirus replicon particle vaccine for cytomegalovirus. Vaccine 25(42), 7441-7449 (2007).
212. Bernstein DI, Reap EA, Katen K et al. Randomized, double-blind, Phase 1 trial of an alphavirus replicon vaccine for cytomegalovirus in CMV seronegative adult volunteers. Vaccine 28(2), 484-493 (2009).